FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2960323991> ?p ?o ?g. }

• W2960323991 endingPage "1293" @default.
• W2960323991 startingPage "1293" @default.
• W2960323991 abstract "<h3>Importance</h3> Multiple myeloma is consistently preceded by monoclonal gammopathy of undetermined significance (MGUS). Risk models that estimate the risk of progression from MGUS to multiple myeloma use data from a single time point, usually the initial workup. <h3>Objective</h3> To longitudinally investigate the alterations of serum immune markers with stable vs progressive MGUS. <h3>Design, Setting, and Participants</h3> This prospective cross-sectional cohort study included 77 469 adult participants aged 55 to 74 years in the screening arm of the National Cancer Institute Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial who had a diagnosis of progressing MGUS (n = 187) or stable MGUS (n = 498), including light-chain subtype, from November 1993, through December 2011. For each participant, all available serially stored prediagnostic serum samples (N = 3266) were obtained. Data analysis was performed from April 2018, to December 2018. <h3>Main Outcomes and Measures</h3> Serum protein and monoclonal immunoglobulin levels, serum free light chains, and serum light chains within each immunoglobulin class were measured. <h3>Results</h3> Of 685 individuals included in the study, 461 (67.3%) were men; the mean (SD) age was 69.1 (5.6) years. In cross-sectional modeling, risk factors associated with progressive MGUS were IgA isotype (adjusted odds ratio [OR], 1.80; 95% CI, 1.03-3.13;<i>P</i> = .04), 15 g/L or more monoclonal spike (adjusted OR, 23.5; 95% CI, 8.9-61.9;<i>P</i> < .001), skewed (<0.1 or >10) serum free light chains ratio (adjusted OR, 46.4; 95% CI, 18.4-117.0;<i>P</i> < .001), and severe immunoparesis (≥2 suppressed uninvolved immunoglobulins) (adjusted OR, 19.1; 95% Cl, 7.5-48.3;<i>P</i> < .001). Risk factors associated with progressive light-chain MGUS were skewed serum free light chains ratio (adjusted OR, 44.0; 95% CI, 14.2-136.3;<i>P</i> < .001) and severe immunoparesis (adjusted OR, 48.6; 95% CI, 9.5-248.2;<i>P</i> < .001). In longitudinal analysis of participants with serial samples prior to progression, 23 of 43 participants (53%) had high-risk MGUS before progression; 16 of these 23 (70%) experienced conversion from low-risk or intermediate-risk MGUS within 5 years. Similar results were found for light-chain MGUS. <h3>Conclusions and Relevance</h3> The findings of evolving risk patterns support annual blood testing and risk assessment for patients with MGUS or light-chain MGUS." @default.
• W2960323991 created "2019-07-23" @default.
• W2960323991 creator A5001522697 @default.
• W2960323991 creator A5005425076 @default.
• W2960323991 creator A5008487390 @default.
• W2960323991 creator A5016074876 @default.
• W2960323991 creator A5019866236 @default.
• W2960323991 creator A5024505450 @default.
• W2960323991 creator A5029832651 @default.
• W2960323991 creator A5037297600 @default.
• W2960323991 creator A5041990847 @default.
• W2960323991 creator A5044116320 @default.
• W2960323991 creator A5044552886 @default.
• W2960323991 creator A5046644939 @default.
• W2960323991 creator A5048966043 @default.
• W2960323991 creator A5054205236 @default.
• W2960323991 creator A5057550547 @default.
• W2960323991 creator A5060381494 @default.
• W2960323991 creator A5060701531 @default.
• W2960323991 creator A5062086023 @default.
• W2960323991 creator A5074049305 @default.
• W2960323991 creator A5082004555 @default.
• W2960323991 creator A5085905854 @default.
• W2960323991 date "2019-09-01" @default.
• W2960323991 modified "2023-10-16" @default.
• W2960323991 title "Association of Immune Marker Changes With Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma" @default.
• W2960323991 cites W1973198827 @default.
• W2960323991 cites W1975684011 @default.
• W2960323991 cites W2024081693 @default.
• W2960323991 cites W2027698431 @default.
• W2960323991 cites W2031157863 @default.
• W2960323991 cites W2042745782 @default.
• W2960323991 cites W2075127332 @default.
• W2960323991 cites W2086990334 @default.
• W2960323991 cites W2090476338 @default.
• W2960323991 cites W2132013899 @default.
• W2960323991 cites W2144728882 @default.
• W2960323991 cites W2151638673 @default.
• W2960323991 cites W2170515647 @default.
• W2960323991 cites W2504076934 @default.
• W2960323991 cites W2570618306 @default.
• W2960323991 cites W2742653490 @default.
• W2960323991 cites W2759059720 @default.
• W2960323991 cites W2766264317 @default.
• W2960323991 cites W2783177883 @default.
• W2960323991 cites W2785817645 @default.
• W2960323991 cites W2789928137 @default.
• W2960323991 cites W4237659442 @default.
• W2960323991 cites W4292528167 @default.
• W2960323991 doi "https://doi.org/10.1001/jamaoncol.2019.1568" @default.
• W2960323991 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6646992" @default.
• W2960323991 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31318385" @default.
• W2960323991 hasPublicationYear "2019" @default.
• W2960323991 type Work @default.
• W2960323991 sameAs 2960323991 @default.
• W2960323991 citedByCount "49" @default.
• W2960323991 countsByYear W29603239912019 @default.
• W2960323991 countsByYear W29603239912020 @default.
• W2960323991 countsByYear W29603239912021 @default.
• W2960323991 countsByYear W29603239912022 @default.
• W2960323991 countsByYear W29603239912023 @default.
• W2960323991 crossrefType "journal-article" @default.
• W2960323991 hasAuthorship W2960323991A5001522697 @default.
• W2960323991 hasAuthorship W2960323991A5005425076 @default.
• W2960323991 hasAuthorship W2960323991A5008487390 @default.
• W2960323991 hasAuthorship W2960323991A5016074876 @default.
• W2960323991 hasAuthorship W2960323991A5019866236 @default.
• W2960323991 hasAuthorship W2960323991A5024505450 @default.
• W2960323991 hasAuthorship W2960323991A5029832651 @default.
• W2960323991 hasAuthorship W2960323991A5037297600 @default.
• W2960323991 hasAuthorship W2960323991A5041990847 @default.
• W2960323991 hasAuthorship W2960323991A5044116320 @default.
• W2960323991 hasAuthorship W2960323991A5044552886 @default.
• W2960323991 hasAuthorship W2960323991A5046644939 @default.
• W2960323991 hasAuthorship W2960323991A5048966043 @default.
• W2960323991 hasAuthorship W2960323991A5054205236 @default.
• W2960323991 hasAuthorship W2960323991A5057550547 @default.
• W2960323991 hasAuthorship W2960323991A5060381494 @default.
• W2960323991 hasAuthorship W2960323991A5060701531 @default.
• W2960323991 hasAuthorship W2960323991A5062086023 @default.
• W2960323991 hasAuthorship W2960323991A5074049305 @default.
• W2960323991 hasAuthorship W2960323991A5082004555 @default.
• W2960323991 hasAuthorship W2960323991A5085905854 @default.
• W2960323991 hasBestOaLocation W29603239911 @default.
• W2960323991 hasConcept C126322002 @default.
• W2960323991 hasConcept C141341695 @default.
• W2960323991 hasConcept C143998085 @default.
• W2960323991 hasConcept C159654299 @default.
• W2960323991 hasConcept C163864487 @default.
• W2960323991 hasConcept C188816634 @default.
• W2960323991 hasConcept C203014093 @default.
• W2960323991 hasConcept C2776364478 @default.
• W2960323991 hasConcept C2776855637 @default.
• W2960323991 hasConcept C2777250017 @default.
• W2960323991 hasConcept C2777991845 @default.
• W2960323991 hasConcept C542903549 @default.
• W2960323991 hasConcept C71924100 @default.
• W2960323991 hasConcept C90924648 @default.

• next